Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2813379 | 0.90 | CCR5 (0.43) | DHODHPOLBCCR5SLC18A3CYP1A2 | |
| SCHEMBL8036930 | 0.82 | DHODH (0.56) | DHODHHRH3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL14335802 | 0.81 | HRH3 (0.47) | DHODHHRH3POLBCCR5SLC18A3 | |
| SCHEMBL28438873 | 0.80 | DHODH (0.54) | DHODHHRH3IDO1POLBSMN1; SMN2 | |
| SCHEMBL13232178 | 0.80 | DHODH (0.58) | DHODHHRH3IDO1POLBSMN1; SMN2 | |
| SCHEMBL11981999 | 0.80 | DHODH (0.54) | DHODHHRH3IDO1MEN1KMT2A | |
| SCHEMBL10021103 | 0.80 | DHODH (0.58) | DHODHHRH3IDO1SMN1; SMN2RAB9A | |
| SCHEMBL16995185 | 0.79 | IDO1 (0.53) | DHODHHRH3IDO1LMNAMEN1 | |
| SCHEMBL477415 | 0.79 | IDO1 (0.53) | DHODHHRH3IDO1LMNAMEN1 | |
| SCHEMBL1430742 | 0.79 | IDO1 (0.53) | DHODHHRH3IDO1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721008-B1 | HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES AS P53 (MDM2 OR MDM4) INHIBITORS | NOVARTIS AG (CH) | 2015-04-29 | — | — | EP | disclosed |
| EP-2721008-B1 | HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES AS P53 (MDM2 OR MDM4) INHIBITORS | NOVARTIS AG (CH) | 2015-04-29 | — | — | EP | disclosed |
| US-8859535-B2 | Hydroxy substituted isoquinolinone derivatives | NOVARTIS AG (CH) | 2014-10-14 | — | — | US | disclosed |
| US-8859535-B2 | Hydroxy substituted isoquinolinone derivatives | NOVARTIS AG (CH) | 2014-10-14 | — | — | US | disclosed |
| US-8859535-B2 | Hydroxy substituted isoquinolinone derivatives | NOVARTIS AG (CH) | 2014-10-14 | — | — | US | disclosed |
| US-20140135306-A1 | HDYROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-05-15 | — | — | US | disclosed |
| US-20140135306-A1 | HDYROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-05-15 | — | — | US | disclosed |
| US-20140135306-A1 | HDYROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-05-15 | — | — | US | disclosed |
| EP-2721008-A1 | HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES | Novartis AG (CH) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012175520-A1 | HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2012-12-27 | — | — | WO | disclosed |
| EP-1819670-B1 | 12-ARYL PROSTAGLANDIN ANALOGS | ALLERGAN INC (US) | 2012-08-08 | — | — | EP | disclosed |
| CN-101107225-A | 12-aryl prostaglandin analogs | ALLERGAN INC (US) | 2008-01-16 | — | — | CN | disclosed |
| US-7279478-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2007-10-09 | — | — | US | disclosed |
| EP-1819670-A1 | 12-ARYL PROSTAGLANDIN ANALOGS | Allergan, Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| US-7091231-B2 | 12-Aryl prostaglandin analogs | ALLERGAN, INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060148894-A1 | Z)-7-{(1R,2S,3R)-2-[4-(Cyclohexyl-hydroxy-methyl)-phenyl]-3-hydroxy-5-oxo cyclopentyl}-hept-5-enoic acid methyl ester; treating vision defects | ALLERGAN, INC. (US) | 2006-07-06 | — | — | US | disclosed |
| WO-2006063179-A1 | 12-ARYL PROSTAGLANDIN ANALOGS | ALLERGAN, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| US-20060122268-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2006-06-08 | — | — | US | disclosed |
| EP-1537074-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004022526-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148894-A1 | Z)-7-{(1R,2S,3R)-2-[4-(Cyclohexyl-hydroxy-methyl)-phenyl]-3-hydroxy-5-oxo cyclopentyl}-hept-5-enoic acid methyl ester; treating vision defects | ALOX5, PTGER2, PTGER1 | DHODH 1439/4885HRH3 612/4885IDO1 1921/4885 |
| US-20060122268-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSK | DHODH 3958/4885HRH3 1735/4885IDO1 3893/4885 |
| US-20140135306-A1 | HDYROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES | MDM4, MDM2, TP53 | DHODH 108/4885HRH3 1730/4885IDO1 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.